Joshua R. Korzenik

Inflammatory bowel disease and environmental influences.

Association of glycogen storage disease 1b and Crohn disease: results of a North American survey.

Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor.

Infliximab maintenance therapy for fistulizing Crohn's disease.

Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.

Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators.

Sargramostim for active Crohn's disease.

Probiotics for recurrent Clostridium difficile disease.

Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease.

Evolving knowledge and therapy of inflammatory bowel disease.

Risks and benefits of infliximab for the treatment of Crohn's disease.

Analysis of treatment effects on the microbial ecology of the human intestine.

Case closed? Diverticulitis: epidemiology and fiber.

Growth factors as treatment options for intestinal inflammation.

Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes.

Crohn's disease: innate immunodeficiency?

Flare factor: are there any triggering factors associated with onset of clinical symptoms or disease relapse?

Diverticulitis: new frontiers for an old country: risk factors and pathogenesis.

Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire.

Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists.

Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy.

Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease?

Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent.

Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis.

LRRK2 is involved in the IFN-gamma response and host response to pathogens.

Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.

Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.

Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis.

Higher predicted vitamin D status is associated with reduced risk of Crohn's disease.

Barriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives.

Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.

Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease.

Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases.

Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease.

A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis.

Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals.

Marijuana use patterns among patients with inflammatory bowel disease.

Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts.

SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease.

Impaired innate immune function associated with fecal supernatant from Crohn's disease patients: insights into potential pathogenic role of the microbiome.